Enoxaparin (Lovenox) for Acute ST-Segment Elevation Myocardial Infarction

Enoxaparin sodium injection (Lovenox, Sanofi-Aventis) is now approved for the treatment of acute ST-segment elevation myocardial infarction (STEMI). STEMI is a severe type of heart attack in which an artery is usually completely blocked by a blood clot long enough to cause heart muscle damage.

An anticoagulant, enoxaparin is approved in the U.S. for the prevention of ischemic complications of unstable angina and non-ST-segment elevation (NSTEMI) when administered with aspirin and for preventing DVT, which can lead to PE. It is also indicated for abdominal surgical patients and immobile, acutely ill patients at risk for thromboembolic complications; patients undergoing hip or knee replacement surgery; patients with acute DVT, with or without PE, when given with warfarin (Coumadin generic, Bristol-Myers Squibb); and outpatients with acute DVT without PE, when given with canadian warfarin.